Yasukata Ohashi1,2, Megumi Yatabe3, Daisuke Niijima3, Arina Imamura3, Yoshiyuki Nagayama3, Kentaro Otsuka3, Yutaka Yachi3, Hironori Ueno4, Takahiro Yano4, Nobuaki Mori5, Koji Higai2, Akihiro Yokoyama4,6. 1. Department of Pharmacy, National Hospital Organization Tokyo Medical Center, Tokyo, Japan; yasu970554126@gmail.com. 2. Department of Medical Biochemistry, Faculty of Pharmaceutical Sciences, Toho University, Chiba, Japan. 3. Department of Pharmacy, National Hospital Organization Tokyo Medical Center, Tokyo, Japan. 4. Division of Hematology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan. 5. Department of General Internal Medicine and Infectious Diseases, National Hospital Organization Tokyo Medical Center, Tokyo, Japan. 6. Division of Transfusion Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Abstract
BACKGROUND/AIM: The importance of compliance with National Comprehensive Cancer Network (NCCN) guidelines for preventing varicella-zoster virus reactivation (VZVr) in multiple myeloma (MM) in a clinical setting has not been well investigated. PATIENTS AND METHODS: We retrospectively studied the clinical characteristics and outcomes of 118 patients with MM treated with proteasome inhibitors. RESULTS: Thirty-nine episodes of VZVr were observed in 37 patients (VZVr group). The proportion of prophylactic antiviral prescriptions and compliance with antiviral prophylaxis based on the NCCN Clinical Practice guidelines was 76% and 30% in the VZVr group, and 88% and 74% in the non-VZVr group, respectively. Multivariate analysis showed that compliance with the NCCN guidelines was the only independent risk factor for VZVr (p=0.0017). CONCLUSION: It is important that prophylactic antivirals are prescribed for an appropriate duration of time to prevent the reactivation of VZV in compliance with existing guidelines.
BACKGROUND/AIM: The importance of compliance with National Comprehensive Cancer Network (NCCN) guidelines for preventing varicella-zoster virus reactivation (VZVr) in multiple myeloma (MM) in a clinical setting has not been well investigated. PATIENTS AND METHODS: We retrospectively studied the clinical characteristics and outcomes of 118 patients with MM treated with proteasome inhibitors. RESULTS: Thirty-nine episodes of VZVr were observed in 37 patients (VZVr group). The proportion of prophylactic antiviral prescriptions and compliance with antiviral prophylaxis based on the NCCN Clinical Practice guidelines was 76% and 30% in the VZVr group, and 88% and 74% in the non-VZVr group, respectively. Multivariate analysis showed that compliance with the NCCN guidelines was the only independent risk factor for VZVr (p=0.0017). CONCLUSION: It is important that prophylactic antivirals are prescribed for an appropriate duration of time to prevent the reactivation of VZV in compliance with existing guidelines.
Authors: Adriana Bastidas; Javier de la Serna; Mohamed El Idrissi; Lidia Oostvogels; Philippe Quittet; Javier López-Jiménez; Filiz Vural; David Pohlreich; Tsila Zuckerman; Nicolas C Issa; Gianluca Gaidano; Je-Jung Lee; Sunil Abhyankar; Carlos Solano; Jaime Perez de Oteyza; Michael J Satlin; Stefan Schwartz; Magda Campins; Alberto Rocci; Carlos Vallejo Llamas; Dong-Gun Lee; Sen Mui Tan; Anna M Johnston; Andrew Grigg; Michael J Boeckh; Laura Campora; Marta Lopez-Fauqued; Thomas C Heineman; Edward A Stadtmauer; Keith M Sullivan Journal: JAMA Date: 2019-07-09 Impact factor: 56.272
Authors: Veronique Erard; Katherine A Guthrie; Cara Varley; Judson Heugel; Anna Wald; Mary E D Flowers; Lawrence Corey; Michael Boeckh Journal: Blood Date: 2007-05-21 Impact factor: 22.113
Authors: Asher Chanan-Khan; Pieter Sonneveld; Michael W Schuster; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Rachel Neuwirth; Kenneth C Anderson; Paul G Richardson Journal: J Clin Oncol Date: 2008-08-18 Impact factor: 44.544